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ABSTRACT
It is estimated that one in 59 children in the US are affected by autism spectrum disorder
(ASD). ASD is distinguished by social and communication deficits that can be displayed
throughout a wide range of severity. This resulting spectrum of behaviors observed in ASD
suggests that a complex etiology is involved. Previous studies have shown a genetic
susceptibility to autism including paternal age, twin and sibling concordance. Genetic
sequencing of those affected as well as first order relatives have identified alterations in genes
associated with neuronal synaptic communication. However, very little information is available
regarding the pathophysiology of synapses in ASD. Neuronal communication between anterior
cingulate cortical neurons via synapses with other brain regions is vital in the execution of social
behaviors in individuals. The aim of this study was to evaluate the protein expression of the
synaptic marker spinophilin and post-synaptic density protein-95 (PSD-95) in postmortem ASD
gray matter brain tissue from the anterior cingulate and frontal cortex to compare to typically
developing (TD) control brain tissue. Postmortem brain tissue of ASD and TD subjects was
acquired from nationally funded brain repositories previously matched by brain area, age and
gender. Immunoblotting for spinophilin and PSD-95 was performed using anterior cingulate and
frontal cortical gray matter brain tissue from matched ASD and TD brain tissue. Spinophilin and
PSD-95 protein amounts for all donors were normalized using GAPDH. Frontal cortical tissue
demonstrated no significant differences in spinophilin protein expression between TD and ASD
groups (N=6). Anterior cingulate tissue demonstrated no significant differences in spinophilin
protein expression between TD and ASD groups (N=5). PSD-95 protein expression levels did
not result in any significant differences between ASD donors and their control pairs for either
brain tissue region. Although no changes were detected in the frontal cortex or anterior cingulate
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cortex, more brain areas and subjects must be evaluated to determine if spinophilin or PSD-95
can be reliable markers for synaptic alterations in ASD. These data are critical in determining
synaptic pathology in ASD which may lead to future treatments.

ABBREVIATIONS: Autism Spectrum Disorder (ASD), Gastrointestinal (GI), Typically
Developing (TD), Brodmann Area (BA), Anterior Cingulate Cortex (ACC), Magnetic resonance
imaging (MRI), Functional MRI (fMRI), Prefrontal cortex (PFC), Gamma- aminobutyric acid
(GABA), Postsynaptic density protein 95 (PSD 95), Immunohistochemistry (IHC), Diagnostic
and Statistical Manual (DSM), Gray Matter (GM), White Matter (WM), Insulin-like growth
factor (IGF1).
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BACKGROUND
Autism Spectrum Disorder (Facts and Behaviors)
Autism Spectrum Disorder (ASD) poses a major concern to society as it is a disorder that
affects many individuals, and has shown a growing trend in numbers. ASD is known as a
spectrum disorder due to the wide range of behaviors that can be displayed in individuals. It can
be categorized by repetitive and specific patterns of behavior that interfere with communication
and social interactions. Assessment of children for ASD include measures of intellectual
functioning and verbal language skills that display varying degrees of impairment. The resulting
‘spectrum’ of behaviors is attributed to a broad range of phenotypes that are classified by levels
of severity suggesting that the complexity of this disorder is not the result of one causal or
determining factor. Intelligence for example is the result of many contributing factors and has
demonstrated varying patterns with ASD symptom severity. One study for example, analyzed the
IQ’s of 75 children diagnosed with ASD and found that 55% of the children fell within the
“intellectual disability” category, 16% were categorized as “moderate to severe intellectual
disability”, 28% demonstrated “average intelligence”, and 3% exhibited “above average
intelligence” (Charman et al., 2010). An older study in 2000 conducted on 27 children diagnosed
with ASD demonstrated that early intervention in 31 to 65-month-olds is imperative and led to
higher quality, educational placement post- treatment (Harris et al). Mayes and Calhoun’s crosslongitudinal study examined 164 3 to 15-year-olds and established that any early speech delays
demonstrated in ASD children did not determine their verbal IQ ability at a later age (2003). The
study of IQ, speech, and behavioral patterns is just one example of the complexity of the
disorder. It is likely an interplay of both genetic abnormalities and environmental factors at
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critical stages of development interact to cause the varying degree of symptoms demonstrated by
ASD.
The prevalence of ASD is astounding. According to the National Institute of Mental Health, a
study done by the CDC’s Autism and Developmental Disabilities Monitoring Network (ADDM)
found that one in every 59 children were diagnosed with ASD in 2014. ASD affects individuals
across all racial and ethnic groups, regardless of socioeconomic status. ASD is found to occur
more commonly in boys than girls, with boys four times as likely to be identified with ASD
(Baio et al., 2014). Additionally, children are more likely to develop ASD if their parents already
have a child with ASD (Ozonoff et al., 2011; Sumi et al., 2006). ASD has a complex etiology as
5% of the ASD population present with an “underlying chromosomal anomaly” (Folstein et al.,
2001). Multiple genes have been identified through genetic sequencing of affected individuals
and family members (Jamain et al., 2003). Genetic changes can directly affect phenotype;
therefore, the genetic profile of individuals with ASD has contributed to our current knowledge
but does not account entirely for development of the disorder. Identical or monozygotic twins,
fraternal or dizygotic twin pairs and regular siblings have been investigated to determine the
genetic similarity in ASD. ASD concordance levels in identical twin studies (where both twins
are diagnosed with ASD) range between 36 to 95%, strongly supporting that additional factors
contribute to the disorder (NINDS, 2015). One particular monozygotic twin study showed a
concordance rate of 60% with the dizygotic pairs demonstrating 0% concordance (Bailey et al.,
1995). While the rates may vary slightly from study to study, it has been consistently shown that
monozygotic twin pairs display a higher risk of ASD concordance than dizygotic twin pairs
(Rosenberg et al., 2009). But, concordance rates of less than 100% in monozygotic twins
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suggests that genes do not entirely account for the ASD risk, but do play some role in the
disorder.
Many possible risk factors have been associated with ASD including parental age (Durkin et
al., 2008). Paternal age played a factor in the diagnosis of ASD, for one study found children
born to fathers 40 years or older were at a greater risk, by a factor of 5.75 (Reichenberg et al.,
2006). While ASD reports have shown a high prevalence in offspring of the non-Hispanic white
race, the diagnosis is not limited to this population. One study examined the factor of maternal
nativity and found that compared to US-born whites, children of foreign-born mothers of
African-American, Central/ South American, Filipino, Vietnamese and US-born Hispanic and
African American ethnicities had a higher risk of ASD diagnosis (Becerra et al., 2014). This
study is significant in that demonstrates the need for future research on how maternal race and
nativity are related to the occurrence of ASD in children. Because ASD crosses all racial and
socioeconomic borders, more studies on parental factors could lead to new findings in regards to
the etiology and pathophysiology of ASD.
In terms of co-occurrence with other diagnoses, individuals with ASD are 83% more likely to
have one or more non-ASD developmental disorders (Levy et al., 2010). While the Diagnostic
and Statistical Manual of Mental Disorders (5th Edition) prohibits ASD and ADHD from being
co-diagnosed, the co-occurrence has recently been reported as common, especially between
children who have ADHD and motor coordination issues (Reiersen & Todd, 2014). Children
with ASD have also been found to suffer from more gastrointestinal symptoms as compared to
control groups (McElhanon et al., 2014). The idea of a “gut-brain axis” has been hypothesized
and examined in numerous studies stemming from this relationship between GI disturbances and
ASD (Rosenfeld, C. S., 2015). The connection between the gut-microbiome and brain is further
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linked by the gut’s closely associated role in the limbic system, controlling “emotionality” (Jones
et al., 2006). Further, it is noteworthy to state that studies have found that the severity of these GI
disturbances is linked with the severity of ASD diagnosis (Adams et al., 2011). Collectively,
these studies strengthen the argument for more research on genetic risks and comorbid disorders
associated with ASD.
The economic burden of ASD is rising as the number of reported cases increases. For
example, in the UK one estimate by the Foundation for People with Learning Disabilities found
the annual cost of supporting children with ASD to total 2.7 billion pounds and roughly 3.5
billion dollars (Knapp et al., 2007). In the US, one study found that compared to children without
ASD, the mean medical expenditure for Medicaid-enrolled children diagnosed with ASD was six
times greater (Peacock et al., 2012). Little research is available for other countries regarding the
economic burden of ASD. However, one study in urban China found that 58% of families with a
child with ASD affected employment outcome (Ou et al., 2015). Additionally, a correlation was
found between the occurrence of ASD and cost of emergency department (ED) visits, for adults
with ASD exhibited mean total ED costs of 2.3 times higher than typically developing (TD)
adults (Vohra et al., 2015). The financial burden that has been associated with autism spectrum
disorder is staggering and it is important to recognize that there are many costly concerns that
families face with ASD.
The behavioral aspects of this disorder vary extensively with most diagnoses occurring
shortly after two years of age. According to the latest version of the Diagnostic and Statistical
Manual of Mental Disorders, the severity of autism is dependent upon the level of “social
communication impairments, and restricted, repetitive patterns of behavior” (American
Psychiatric Association, 2013). Individuals on the spectrum tend to find social interactions
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challenging, and they prefer to spend time alone rather than playing with others (NINDS, 2015).
Parents and educators report that people with ASD may repeat certain phrases, use a monotone
voice, perform high-pitched singing, or simply refrain from talking (NINDS, 2015). It has been
reported that children with ASD will fixate and discuss a particular topic, ignoring the second
participant in the conversation (NINDS, 2015). Furthermore, children with ASD may struggle to
understand and interpret behavioral, nonverbal cues such as waving goodbye, or body language
and its implications. Another common characteristic behavior seen in ASD is an obsession with a
particular activity or item, motion, or word (NINDS, 2015). For example, the action may involve
one specific toy truck and driving it around in circles, or leaning from side to side regardless of
the environment. Individuals with ASD present with varying phenotypes, therefore, an extensive
evaluation consisting of the input of various medical professionals is necessary for an accurate
diagnosis. While there is a spectrum of behaviors, the DSM-5 classifies ASD as being
comprised of the following disorders: early infantile autism, childhood autism, Kanner’s autism,
high-functioning autism, atypical autism, pervasive developmental disorder not otherwise
specified, childhood disintegrative disorder, and Asperger’s syndrome (American Psychiatric
Association, 2013). The number of autism phenotypes indicates a very complex etiology
consisting of multiple factors. It is imperative that more information become available for the
pathophysiology of the disorder. Research that utilizes postmortem tissue can lead to the
identification of the etiology or treatments for ASD.
Neuroanatomical and Neuroimaging Findings in ASD
The identification of neuroanatomical alterations has been a key factor in the current
knowledge regarding the interplay of genetic and environmental contributions. These
abnormalities are thought to begin during the early stages of brain development, thus leading to
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alterations that can be identified through the use of postmortem tissue in deceased individuals
that were diagnosed with the disorder. The pathological changes indicate that communication
between cell types, specifically excitatory and inhibitory neurons in the brain, is not the same as
in a TD age-matched control. Research is lacking for support of this claim. It is known that ASD
has shown neuroanatomical differences as compared to TD age-matched controls. ASD studies
support overgrowth of cortical cells in the frontal cortex of the brain during the early postnatal
period (Donovan et al., 2016). Schumann et al. (2010) provided one of the first major studies to
demonstrate these significant differences where they found that both the gray and white matter of
the cerebral cortex displayed substantial abnormalities in growth. This study also provided
evidence that by the age of 2.5, the most notable discrepancies in volume and other ageassociated differences were found in the anterior brain regions, such as the frontal, temporal and
cingulate regions (Schumann et al., 2010).
Volumetric differences in certain areas of the brain have also been examined in ASD
research. One study found that 90% of boys diagnosed with ASD had a larger brain volume by
years two to four, as compared to the normal average (Courchesne et al., 2001). Researchers are
still trying to determine why there are volumetric differences in postmortem ASD brains; for
example, are there more neurons in a particular area of the brain? One particularly interesting
study using mouse models found that by manipulating the second and third layers of neocortex
by increasing the amount of excitatory neurons led to social-behavioral deficits similar to those
in human ASD (Fang et al., 2014). These findings are significant in showing support for the
excitatory-inhibitory neuronal imbalance. The imbalance is theorized to stem from either
changes to the composition of different neuronal cell types or an over-production of neurons,
leading to an increase in synaptic activity in certain areas of the brain (Fang et al., 2014).
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Regardless of the specific pathophysiology, it is clear that abnormalities observed in ASD stem
from some neuropathological alterations. Collectively, the previous studies mentioned all
highlight the need to identify the pathophysiological differences at a cellular level.
In terms of diagnosis, ASD may be a classified as a behavioral diagnosis, but the underlying
cause of the disrupted social interaction lies in the pathophysiology of the behavior. For this
reason, it is important to examine the pathology of brain regions that contribute to social
behaviors. The brain is one of two main components of the central nervous system, working with
the spinal cord to process information and communicate with the rest of the body via the cranial
and peripheral nervous system. The brain processes and interprets sensory information that is
delivered from the spinal cord and cranial nerves. The frontal cortex plays a key role in higherorder cognitive function meaning that it mediates social behavior, learning, communicating, and
decision making (Donovan et al., 2016). Part of this research study examined Brodmann Area
10, or BA 10, which is solely located in the frontal cortex. The anterior cingulate cortex (ACC) is
a particularly important region in mediating sensory information that is involved in social
behaviors. The ACC receives neuronal signals from the amygdala and then routes those signals
onto the prefrontal cortex where executive function planning takes place. Essentially, the
cingulate coordinates between the sensory (amygdala) and decision making (frontal cortex). The
cingulate cortex can be divided into the ACC and the posterior cingulate cortex (PCC). The ACC
can be further sectioned into the ventral ACC, and the dorsal ACC. This study focuses on
Brodmann Area 24, or BA 24, the ACC area that resembles a backwards “C” shape that
surrounds the corpus callosum. While the ACC functions in a wide range of autonomic functions
such as blood pressure and heart rate regulation, it is significant in ASD studies for its role in
rational cognitive functions (Stevens et al., 2011).
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Magnetic resonance imaging studies have demonstrated differences in the social brain
activation patterns involving the amygdala, anterior cingulate and prefrontal cortical regions
during social tasks. Furthermore, studying these key brain areas through MRI studies can
highlight deviations from typical brain development, providing researchers with more
information on atypical developmental patterns in ASD. The amygdala is a component of the
limbic system that is involved in emotional behaviors and motivations. Using magnetic
resonance imaging, researchers have measured larger amygdala volumes in toddlers diagnosed
with ASD, as compared to their typically developing counterparts (Schumann et al., 2009).
Another key social brain area for MRI studies is the ACC for its role in social impairment, one of
the main deficits displayed in ASD. One functional MRI (fMRI) study found disrupted
functional connectivity and decreased activity in the ACC (Mueller et al., 2013). The prefrontal
cortex is involved in goal-oriented behaviors such as decision making, problem solving, and
social reasoning. For this reason, it has been examined in ASD studies to see if any structural or
functional abnormalities are present. In a comprehensive study of connectivity in ASD, Rane et
al (2015) evaluated numerous prior studies to state that the prefrontal cortex was “most often
reported” to exhibit decreased connectivity with other brain regions. These such connectivity
studies used MRI technology to demonstrate reduced resting state connectivity which could
ultimately play a role in the social and behavioral impairments in ASD, as this reduced
connectivity negatively affects the typical neural pathways (Rane et al., 2015).
Excitatory and Inhibitory Neuronal Imbalances in ASD
Neurons specifically have their own specialized way of communicating within the cell,
enabling the extensive connections previously described to quickly and effectively transmit
neuronal messages. Communication within the nervous system is conducted through electrical
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currents known as action potentials. The action potential is propagated along the axon from the
cell body to the axon terminal (Barak, 2019). One factor that affects the speed of the action
potential’s transmission is the myelin (Barak, 2019). The myelin is an outer covering that
protects the axon while simultaneously providing insulation and increasing the speed of
conductivity (Barak, 2019). Action potentials are facilitated by neurotransmitters.
Neurotransmitters are classified as excitatory or inhibitory due to their ability to promote or
diminish the development of an action potential. Neurotransmitters alter the membrane potential
of cells thus propagating or inhibiting an action potential. The propagation of an action potential
can result in the release of neurotransmitter into the synaptic space and bind to the postsynaptic
neuron to produce an excitatory or inhibitory effect that leads to the facilitation or diminishment
of another action potential.
Glutamate is an excitatory neurotransmitter present in the central nervous system that is
involved in interneural communication. Essentially, glutamate is the primary neurotransmitter
responsible for nerve signaling- where a chemical message is passed from one presynaptic
(sending) nerve cell to a post-synaptic (receiving) nerve cell. Glutamate is responsible for this
communication because when it binds to a specific receptor on nerve cells, it causes positive ions
to flood the cell and effects the action-potential threshold. Ultimately, this increase in membrane
potential will produce a downstream affect where the nerve cell releases neurotransmitters into
the synapse of the receiving cell. If concentrations of glutamate reach abnormally high levels, an
over-excitation of nerve cells can occur. This over-excitation can be harmful as it can ultimately
lead to cell damage or apoptosis, cell death. The glutamate pathways have also been questioned
in ASD research, as this neurotransmitter is equally important in neuronal communication. One
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particular study was able to establish a connection between the reduced density of glutamate and
severity of ASD social impairments (Horder et al., 2018).
Gamma aminobutyric acid (GABA), is the inhibitory neurotransmitter that results in the
diminishment of action potentials in the postsynaptic cells upon binding. In the mature human
brain, GABA is the main inhibitory neurotransmitter, with about 20-30% of cortical interneurons
exhibiting an inhibitory nature (Wu & Sun, 2015). GABA binding to the ionic GABA receptor
will result in a conformational change to allow negative ions outside the cell to enter the neuron.
GABA may also bind to G-protein-coupled receptors, which do not allow ions to follow straight
through, but rather, initiate a signal to other proteins in the cell. This signal will eventually result
in a downstream effect, causing other proteins to change ion channels. The negative ions reduce
the membrane potential and squelch future action potential. Other chemicals can bind to the
GABA receptor at different sites than the neurotransmitter GABA. These chemicals (such as
benzodiazepine in certain medications used to treat anxiety) will work to reduce the neuron’s
activity level. Additionally, GABA-agonists have been used to treat seizure disorders. The high
comorbidity of seizure disorders such as epilepsy with ASD supports an association between
ASD and GABAergic functioning (Kang & Barnes, 2013).
There has been significant evidence that patients with ASD exhibit a substantial amount of
dysregulation within the inhibitory GABA system, leading to issues in neuronal connectivity and
communication (Blatt et al., 2011). By examining postmortem brain tissue, researchers over the
last three decades have found a connection between ASD and lower amounts of GABAergic
cerebellar Purkinje cells in the cerebellar region (Blatt et al., 2011). While the GABAergic
discrepancies seen in ASD can be found in several brain regions, the ACC is of particular
interest with its role in rational and cognitive function. Oblak et al (2009) found a reduction of
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48% in the density of a specific type of GABAergic receptors located in the superficial layer of
the cerebral cortex, and a 20.2% decrease in the deep layers of the ACC. Another study
examined the association between GABA levels and children with ASD, finding decreased
sensorimotor GABA levels in contrast with the TD controls (Puts et al., 2016).
Clearly, GABA and glutamate alterations have been supported in the pathophysiology of
ASD. The findings may be the result of increased glutamate activity or reduced GABAergic
function at the synapse. It is simply unknown whether there is too much gas represented by
glutamate or not enough brakes represented by GABA in ASD. Future studies are needed to
determine neurotransmitter-specific changes.
Synaptic studies using postmortem tissue comparing donors with ASD and TD would greatly
enhance the understanding of cellular communication in ASD. Spinophilin is a protein that is
found in the spines of dendritic processes (Feng et al., 2000). Further, spinophilin is
characterized as a marker for glutamatergic synapses, where excitation signaling occurs. The
dendritic processes are very specific binding areas that serve as hosts in the central nervous
system for a large amount of excitatory input (Feng et al., 2000). Feng et al., found that
spinophilin is essential for regulating the development of characteristics of dendritic spines as
shown in spinophilin-deficient mice (2000). This study also demonstrated that the mice had
adverse effects in their neuronal connections as a result of the “dysregulation of glutamate
receptor currents” (Feng et al., 2000). Further, spinophilin deficient mice showed a overall
reduced brain size, particularly evident in the hippocampus (Feng et al., 2000). Currently,
spinophilin expression has not been examined in brain donors with ASD. It is important to show
glutamatergic synaptic marker alterations in ASD as compared to TD brain donor tissue. ASD is
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currently only described as a behavioral disorder; thus, highlighting the need for identification of
molecular markers that could provide therapeutic or etiological targets at a molecular level.
Postsynaptic density protein 95, or PSD 95 is another synaptic marker protein that, as its
name suggests, tags postsynaptic areas. Specifically, PSD 95 is localized to the postsynaptic
areas which represent asymmetric synapses. In the cerebral cortex, synapses can be categorized
as symmetrical or asymmetrical, depending upon the width of the synaptic junctions.
Asymmetric synapses are characterized by a larger, more prominent postsynaptic density, as
compared to the presynaptic density. These types of synapses represent about 80% of the total
population, meaning that a majority of the synapses are excitatory in function, as compared to
symmetric synapses which are inhibitory. In shape, asymmetric synapses are disproportionate as
they are formed by axon terminals encapsulating spherical synaptic vesicles. There is a large
postsynaptic density found at asymmetrical synapses, and this accounted for by dendritic shafts,
spines and the cell bodies of the inhibitory neurons.
Both of these markers can be used to measure the synaptic density in a specific area of the
brain. It is important to measure and examine synaptic density and its correlation to dendritic
spines as this is important in relation to the quantification of proteins and subsequent
pathophysiology of ASD. Immunohistochemistry (IHC) involves tagging specific proteins in a
tissue sample with a particular primary antibody, and using detection reagents to create a visual
of the target protein in the sample. The detection reagents used can create fluorescent staining
images, such as those generated in this study on spinophilin. From the staining image, the
protein’s level and distribution in the tissue sample are revealed. For this reason, IHC was
utilized in an analysis of spinophilin expression in post-mortem brain tissue of ASD.
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HYPOTHESIS
We hypothesize that synaptic protein expression of spinophilin and PSD-95 will be increased in
the frontal cortex and anterior cingulate cortex of donors that were diagnosed with ASD when
compared to typically developing control brain tissue.
METHODS AND MATERIALS
Brain Tissue
The ASD and TD control donor tissue were obtained from AutismBrainNet (formerly the
Autism Tissue Program and the Harvard Brain Tissue Resource Center in Belmont, MA) and
NIH NeuroBioBank (formerly the NICHD Brain and Tissue Bank for Developmental Disorders
in Baltimore, MD). Tissue brain banks provide medical records, clinical information, and
postmortem tissue information including brain area, pH and RNA integrity number when
available. ASD and TD control donor tissue were matched as closely as possible by brain
region, age, gender, pH and RNA quality as shown in Table 1. Tissue was matched a-priori by
the brain banks. Control donors died as a result of heart attack, asphyxia, drowning and trauma.
Cause of death for the ASD donors included asphyxia, heart failure, respiratory distress, trauma,
ketoacidosis, and bowel obstruction. To uphold a level of respect and protect the identity of the
donors, cause of death for individuals is not included in Table 1 with the donor. ASD donors
were confirmed in their diagnosis through the postmortem Autism Diagnostic Interview- Revised
(ADI-R) or through medical record analysis. Additionally, ASD donors met the standards
established for diagnosis in the DSM V criteria.
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Table 1. Subject Demographic Information
Pair
1

ID
Controls
AN14757

2

Age

Gender

RIN

Assay

Tissue

24

M

7.8

WB

BA10,
BA24

4848

16

M

7.6

WB

BA10,
BA24

3

5342

22

M

8.1

WB

BA10,
BA24

4

5079

33

M

7.3

WB

BA10,
BA24

5

M3231M

37

M

7.4

WB

BA10,
BA24

6

AN12137

31

M

7.3

WB

BA10

MEAN

27.2

7.6

7.8

0.32

SD

1

ASD
AN04166

24

M

8.1

WB

BA10,
BA24

2

5302

16

M

6.6

WB

BA10,
BA24

3

5176

22

M

7.1

WB

BA10,
BA24

4

5297

33

M

7.1

WB

BA10,
BA24

5

5027

37

M

7.7

WB

BA10,
BA24

20

6

AN11989

MEAN

SD

30

27

7.7

M

7.7

WB

BA10

7.4

0.55

RIN, RNA integrity number
WB, Western Blotting

Tissue Sample Preparation and Sectioning
Postmortem human brain tissue was sectioned at a varying thickness depending on the
experiment at -20 degrees Celsius using a cryostat microtome (model Leica CM3050S). Tissue
used for immunohistochemistry was sectioned at 20 μM thickness and placed on positively
charged glass slides followed by storage at -80oC. IHC also used control donor brain tissue that
was paraffin embedded brain tissue after fixation with formaldehyde. Tissue was sectioned to
4μM thickness using a microtome. Tissue used for immunoblotting was sectioned at 50 μM
thickness and punch-dissected at 3.5 μM using a trephine punch tool in gray or white matter for
each brain regions. Tissue was placed in 1.5 ml eppendorf tubes and stored at -80oC. All ASD
and TD pairs were sectioned at the same time and subjected to the same storage time in the ultralow storage freezers.
Immunohistochemistry
IHC using antibodies specific for spinophilin was used to visualize interneural synaptic areas,
specifically at the dendritic spines. In brief, frozen tissue mounted onto glass slides was removed
from the ultra-cold -80°C storage freezer and incubated at room temperature for 20 minutes in a
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ventilated hood. Human tissue was fixed in acetone (10 minutes) and washed one time in
phosphate buffered saline solution or PBS (3 times for 5 minutes). The tissue was enclosed with
a silicone-based pen to create a waterproof barrier in which 1-3 drops of peroxidase blocking
reagent were placed (5 minutes). A gentle rinse and wash using PBS were completed (5
minutes). Goat serum blocking reagent was placed on the tissue, 1-2 drops per sample on the
slide (15 minutes). A quick rinse was performed with PBS. The attempted protocols for antibody
specificity completed during the optimization process can be found in sequential order in Table
2. In brief, formalin-fixed paraffin embedded human brain tissue was sectioned at 4uM
thickness onto supercharged slides. Slides were deparaffinized using a xylene and a series of
ethanol hydration steps proceeding from 100%, 95%, 70%, and 50% followed with a cold-water
rinse. Antigen retrieval was performed using sodium citrate at pH 6.0 at a 95oC incubation for
20 minutes, followed with three washes of buffer without detergent. The protocols using the
peroxidase and serum blocking reagents were performed as stated above. Optimization steps are
summarized in Table 2.
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Table 2. Attempted protocols for the Spinophilin immunohistochemical stain on fixed and frozen
human brain tissue

Block

1x
PBS*

1x
PBS

1x
PBS

1x
PBS

Blocking
Reagent KitPeroxidase
Blocking
Reagent and
Serum
Blocking G
Blocking
Reagent KitPeroxidase
and Serum
Blocking G
Blocking
Reagent KitPeroxidase
and Serum
Blocking G
Blocking
Reagent KitPeroxidase
and Serum
Blocking G

Primary
Antibody
Manufacturer
and Dilution

Components
for Primary
Antibody
Incubation

Secondary
Antibody
Manufacturer
and Dilution

Components
for Secondary
Antibody
Incubation

Developer

Cell Signaling
Technology cat.
14136S, 1:500

1mL PBS
2 uL rabbit
spinophilin
20uL goat
serum

Thermo Fisher
Scientific cat.
no. (HRP)
31460,
1:1000

1 mL PBS
1 uL goat anti
rabbit 4412S

DAPI

1mL PBS
2uL rabbit
spinophilin
20uL goat
serum
1mL PBST
4uL rabbit
spinophilin
15 uL goat
serum (NGS)
1mL PBST
4uL rabbit
spinophilin
15 uL goat
serum (NGS)
Positive Tissue
sample:
1mL PBST
4uL rabbit
spinophilin
15 uL goat
serum (NGS)

Thermo Fisher
Scientific cat.
no. (HRP)
31460,
1:1000
Thermo Fisher
Scientific cat.
no. (HRP)
31460,
1:1000
Thermo Fisher
Scientific cat.
no. (HRP)
31460,
1:1000

1mL PBS
1uL goat anti
rabbit 4412S

DAPI

1mL PBS
1uL goat anti
rabbit 4412S

DAPI

1mL PBS
1uL goat anti
rabbit 4412S

DAPI

Thermo Fisher
Scientific cat.
no. (HRP)
31460,
1:1000

Both Positive
and Negative
Tissue
Samples
Receive:
1mL PBS
1uL goat anti
rabbit 4412S

DAPI

DAPI

DAPI

Cell Signaling
Technology cat.
14136S, 1:500

Cell Signaling
Technology cat.
14136S, 1:250

Cell Signaling
Technology cat.
14136S, 1:250

Blocking
Reagent KitPeroxidase
and Serum
Blocking G

Cell Signaling
Technology cat.
14136S, 1:250

1x
PBS

Blocking
Reagent KitPeroxidase
and Serum
Blocking G

Cell Signaling
Technology cat.
14136S,
1:250

1mL PBST
4uL rabbit
spinophilin
15 uL goat
serum (NGS)

NA

Negative:
Neither tissue
received
secondary AB

1x
PBS

Blocking
Reagent KitPeroxidase

NA

Negative: No
Primary AB

Thermo Fisher
Scientific cat.
no. (HRP)
31460,

Take 2mL of
0.5% BSA in
PBS-T, place
1uL in aliquot

1x
PBS

Negative
tissue sample:
1 mL PBS-T
15 uL goat
serum (NGS)
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and Serum
Blocking G

1x
PBS

1x
PBS*

Blocking
Reagent KitPeroxidase
(5 minutes)
and Serum
Blocking G
(15 minutes)
and 3% BSA
in PBS-T
Block (1 hr)
Blocking
Reagent KitPeroxidase
(5 minutes)
and Serum
Blocking G
(15 minutes)
and 3% BSA
in PBS-T
Block (1 hr)

1:1

NA

NA

Negative:
1mL PBST
15 uL goat
serum (NGS)

Negative:
1 mL PBST

and add 1uL
goat anti rabbit

Thermo Fisher
Scientific cat.
no. (HRP)
31460,
1:1

1uL goat anti
rabbit
1uL 0.5%
BSA in PBS-T

DAPI

1:500

0.0050 g BSA
in 1 mL PBST
2 uL donkey
anti-rabbit

DAPI

*indicates FROZEN human brain tissue, all other attempted protocols were fixed human tissue.
Blocking Reagent KitBSA-Bovine Serum Albumin (BSA) (Fraction V) sourced from Fisher BioReagents cat. 9048-46-8
NGS- Normal Goat Serum in Secondary Antibody sourced from Jackson ImmunoResearch Laboratories
DAPI- ProLong Gold antifade reagent with DAPI sourced from Life Technologies Corporation

Immunoblotting
Brain tissue homogenates from either the anterior cingulate or the frontal cortex were
obtained from the -80oCelsius ultra cold freezer. Triton-EDTA (TE) homogenation buffer (pH
7.4) was added to tissue homogenates while in the freezer. Optimization steps included using
radio immunoprecipitation assay (RIPA) buffer (50mM Tris·HCl, pH 8.0, 150 mM NaCl, .1%
Triton X-100, .5% sodium doxycholate, .1% SDS) for homogenization, but did not provide the
quality of homogenizing using TE buffer. Protease and phosphate inhibitors (PPI) were added at
100-fold concentrations to buffer prior to addition to tissue homogenates. Two hundred
microliters of TE buffer was added to the frozen tissue homogenates. The mixture was placed on
ice after vortexing for ten seconds. The tissue mixture was sonicated twice for ten seconds and
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kept on ice prior protein assay. A five-time loading buffer consisting of betamercaptoethanol
(BME) and Lameli buffer was prepared. Fifty microliters of the BME-Lameli mixture was added
to 150 μL of tissue homogenate and heated to 95oC for 5 minutes. Denatured proteins were
cooled on ice, aliquoted and frozen at -80oC until the next day. Protein concentrations were
determined using a Lowery-based commercial assay with a standard curve of BSA in PBS
solution (Pierce). Twelve micrograms of protein was determined to be the optimal protein
amount for spinophilin in the frontal cortex. Six micrograms of protein was used in the anterior
cingulate cortex. Denatured proteins were separated by an SDS-polyacrylamide gel
electrophoresis (BioRad, Mini PROTEAN TGX Gels). Ten microliters of Precision Protein
standard ladder (Bio-Rad) was used for each TGX gel. Gel electrophoresis was performed for 90
minutes at 100 volts. Proteins were transferred onto a nitrocellulose membrane (BioRad cat.
#1620115 using 100 volts for 60 minutes being careful to not surpass 0.3 Amps). Protein transfer
from the SDS-polyacrylamide gel onto the nitrocellulose membrane was confirmed through a
Poncheau S Stain (SIGMA-ALDRICH- 0.1% Ponceau S, 5% acetic acid, cat #SLCB3855) for 10
minutes. Afterwards, the membrane was rinsed and washed with tris-buffered saline solution
with tween 20 (.2%) or TBS-T (5 minutes) until the red stain color disappears. Membranes were
then blocked with five percent nonfat milk solution (1.25 grams of evaporated milk in 25 mL of
PBS-T) for one hour at room temperature. The membrane was incubated with primary antibody
(6 mL of 5% milk in PBS-T with 6uL of spinophilin) in a Falcon tube on an oscillator overnight
at 4oC. The membrane was washed with PBS-T (3 times for 5 minutes each) the next morning,
followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibody.
Secondary antibody components for spinophilin were 20mL of PBS-Tween with 2 μL of antiRabbit HRP. The membrane was incubated for two hours on a rocking platform and thenwashed
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with PBS-T (3 times for 5 minutes). Chemiluminescent signals were identified using Lumagen
reagents and identified using the BioRad ChemiDoc. In preparation for a new primary antibody,
the membrane was washed with TBS-T (3 times for 5 minutes) and protein was removed or
stripped using a mild stripping buffer for 10 minutes. A wash with TBS-T (2 times for 5 minutes)
was performed before blocking the membrane in 5% nonfat dry milk for one hour. A quick rinse
with TBS-T was completed (3 times for 5 minutes) and the blot was ready for incubation with
the second primary antibody of interest, PSD-95. Paired ASD and TD control tissue samples
were run on the same gel and performed in duplicate. Table 3 highlights antibodies and their
appropriate secondary antibody and Table 4 displays recipes for common buffers used
throughout the immunoblotting process.
Data Analysis
Data were normalized to GAPDH measured on the same blot, after stripping Spinophilin and
PSD-95 antibodies. The blots were then analyzed and quantified using the ImageLab software.
The observed band intensities were measured densitometrically, and numerically expressed as
volume changes relative to the normal, typically developing tissue pair, age and gender matched
via NIH. Band intensities were converted into a numerical value or “adjusted volume” by
creating identical boxes around the band measurements for each pair. Once an adjusted volume
was found for each pair for each respective protein (spinophilin, PSD-95, and GAPDH), the
values for each individual were averaged from the two blots. The protein expression levels were
normalized by dividing their average expression level by GAPDH’s average. This normalization
provided a ratio for each control and ASD donor pair, representing a numerical value that can be
used in comparison.

26

Micro BCA Protein Assay Kit used was sourced from ThermoScientific Ref. 23235 Lot.
SI252807

Table 3: Antibodies
Protein

Source

Spinophilin*

Cell Signaling Technology cat. 14136S

PSD-95*

Cell Signaling Technology cat. 3450S

GAPDH*

EMD Millipore cat. 2955484

Goat anti Rabbit

GE Healthcare UK Limited cat. NA934-1

Donkey anti mouse IgG HRP

GE Healthcare UK Limited cat. NA931V

*indicates a primary antibody
Table 4: Buffers
Buffers

Components or Source

RIPA

Cell Signaling Technology cat. 4370

TE-lysis

(TrisHCl- EDTA) Fisher Scientific

Loading (Lameli)*

4x Lameli Sample Buffer, BioRad Laboratories cat. 161-0747

10x Transfer Stock**

800mL distilled water, 30.3g Tris (Tris base), 144.1 g Glycine
Dilute to 1L

10x Running Stock***

800mL distilled water, 30.4g Tris (Tris base), 144.2 g Glycine,
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and 10.0 g of SDS. Dilute to 1L
Mild Stripping Buffer

15g Glycine, 1g SDS, 10mL Tween20, pH 2.2, bring to 1L

Note:
*A 10% BME (beta kappa ethanol) is added to the loading buffer, as it breaks the protein up and
elongates it in the gel. An amount of 20 μL to 180 μL of loading buffer.
**For the transfer buffer in transfer step, take 100mL from the 10X stock, add 200mL of
methanol and then dilute to 700 mL with water. Place in the fridge for 20 minutes as it needs to
be cold before use. Additionally, the methanol is only necessary if using nitrocellulose blotting
paper, which this protocol uses.
***The running buffer used in the gel electrophoresis is also a dilution of the 10x stock. To prep
the running buffer, obtain 100mL of running buffer and add 900mL of distilled water.
RESULTS
Immunohistochemistry Analysis of Gray Matter Spinophilin
ASD and TD control donor brain tissue were carefully paired by brain banks prior to the start
of the study. Tissues were matched to reduce difference between the pairs for age, gender, RIN
(RNA- integrity number), and post-mortem interval period. Representative images of the
immunohistochemistry identification procedure is shown in Figure 1 using spinophilin primary
antibodies in formalin fixed human postmortem BA10 Gray Matter (GM) brain tissue. Panel A
is an image taken from brain tissue that was incubated with spinophilin antibody followed by an
incubation with the green fluorescent-conjugated secondary antibody (Figure 1, Panel A). Panel
B show 4’6-diamidino-2-phynylindole (DAPI) conjugated along with the green-conjugated
secondary antibody (Figure 1, Panel B). Panels C and D are images that were taken from tissue
that was serially sectioned but did not utilize the spinophilin antibody Figure 1, (Panel C, D).
The illuminated blue dots are 405 fluorescent-conjugated molecule that produces a wavelength at
405 nanometers under a microscope as it binds to adenine-rich regions in DNA. DAPI serves as
a useful indicator of the nucleus region of each individual cell in a tissue stain to visualize all
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cells that are present in the tissue sample. It was found that there was non-specific secondary
binding to the tissue in the negative stain as evident in Figure 1-Panel C and D. No green
fluorescence should be visible in the negative gray matter tissue stain. Table 2 includes the
specific details of every optimization procedure for the spinophilin antibody. Figure 2 exhibits
representative images of the same spinophilin-positive (Panel A & B) vs Negative (Panel C &D)
immunohistochemistry of fixed human postmortem BA10 brain tissue using white matter (WM)
tissue of this tissue sample. Interestingly, there was no binding of the green-fluorescent
conjugated antibody in the white matter. White matter only has ten percent of the neurons found
in gray matter. Therefore, it was likely nonspecific antibody binding to only neurons.
A

C

B

D

Figure 1: GRAY MATTER- Human gray matter (GM) brain tissue using spinipholin antibodies
(positive) followed with GFP-conjugated secondary antibodies for immunohistochemical
identification taken at 20X magnification (Panel A); Human GM 20X DAPI and GFP Positive
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Stain (Panel B); GM 20X GFP immunohistochemistry without the use of spinophilin primary
antibody (Panel C); Human GM 20X DAPI and GFP immunohistochemistry without the use of
spinophilin primary antibody (Panel D).

A

B

C

D

Figure 2: WHITE MATTER- Human white matter (WM) brain tissue using spinipholin
antibodies (positive) followed with GFP-conjugated secondary antibodies for
immunohistochemical identification taken at 20X magnification (Panel A); Human WM 20X
DAPI and GFP Positive Stain (Panel B); WM 20X GFP immunohistochemistry without the use
of spinophilin primary antibody (Panel C); Human WM 20X DAPI and GFP
immunohistochemistry without the use of spinophilin primary antibody (Panel D).

Western Blot Analysis of Gray Matter Spinophilin and PSD95
Spinophilin and PSD-95 protein amounts were measured in two different human brain
regions, including frontal and anterior cingulate cortical gray matter areas, using immunoblotting
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or Western Blotting comparing ASD to TD control donor tissue. There was no statistical
difference between typically developing tissue and ASD for either brain region, in both
spinophilin and PSD-95.
Spinophilin protein expression is showin in Figure 3 for two different brain regions, BA10 or
frontal cortex (N=6) and BA24 or anterior cingulate cortex (N=5). An unpaired Student’s t- test
was used to determine that no statistical significance was found in the frontal cortex (BA10)
when comparing spinophilin protein amounts in ASD donor tissue to TD donor tissue. (Figure
3). Likewise, no statistical difference was found in spinophilin expression in the cingulate cortex
(BA24) between TD and ASD donor tissue. A small sample was used, and more research must
be completed to validate this finding.

Figure 3. Spinophilin Protein Expression determined by immunoblotting in human postmortem
tissue from frontal cortex or BA10 (N=6) and anterior cingulate or BA24 (N=5) punch dissected
brain tissue from TD control tissue (black bars) and ASD tissue (gray bars). Spinophilin protein
expression was normalized the protein expression of a stable reference protein (GAPDH) on the
same blot. No significant difference was observed using an unpaired Student’s t-test.
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Protein expression levels for PSD95 for the two different brain areas, BA10 (N=6) and
BA24 (N=5) are shown in Figure 4. Expression levels for PSD-95 expression were not
signiﬁcantly different in both frontal cortex (BA10) and cingulate (BA24) tissue samples,
analyzed using an independent unpaired Student’s t-test.

Figure 4. PSD-95 Protein Expression determined by immunoblotting in human postmortem
tissue from frontal cortex or BA10 (N=6) and anterior cingulate or BA24 (N=5) punch dissected
brain tissue from TD control tissue (black bars) and ASD tissue (gray bars). Spinophilin protein
expression was normalized the protein expression of a stable reference protein (GAPDH) on the
same blot. No significant difference was observed using an unpaired Student’s t-test.

To determine if differences could be identified in isolated paired tissue samples, a paired
Student’s t-test analysis was performed. All subjects were gender, age, PMI, and RIN matched as
closely as possible; therefore, the possibility exists that paired analysis may better reflect protein
expression differences based on the different developmental stages of the tissue. It is important
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to recognize if perhaps increases may occur in an ASD compared to the paired control donor,
rather than looking at the group as a whole. Since subjects (as pairs) varied in age, it was
determined that a paired analysis could account for the age difference. The data was evaluated
for outliers using a Grubb’s test. The results of a paired T-test for spinophilin protein expression
is shown for each brain area in Figure 5. In each brain area, only one pair showed an increase in
spinophilin protein expression, when comparing control to ASD donors.; however, this pair was
not the same in both areas. Table 5 shows the P values that were gathered to assess the
significance of the differences between control donors and ASD donors in terms of Spinophilin
protein expression for the two different brain areas analyzed in this study.

A

B

Figure 5. Levels of spinophilin protein expression in punch-dissected gray matter from frontal
cortex or BA10 (N=6; panel A) and anterior cingulate cortex or BA24 (N=5; panel B) using a
paired Student’s t-test. Target protein or spinophilin in this figure was normalized to the
reference protein, GAPDH. No significant differences were found.
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T-Test

P-Value
BA10

P-Value
BA24

Unpaired

0.4368

0.674

Paired

0.3893

0.7598

Table 5. Statistical values of an unpaired and paired Student’s t-test for human postmortem
frontal (BA10) and cingulate (BA24) brain tissue of spinophilin protein expression between ASD
and TD control tissue.

RESULTS (cont’d)
Figure 6 displays the results of a paired Student’s t-test for PSD-95 expression levels in both
BA10 and BA24 brain regions upon comparing ASD and TD donor tissue. No trending data
emerged from the graphed information. Two pairs had increased PSD-95 expression in TD when
compared to ASD tissue in BA10. In the paired analysis for BA24, one pair exhibited an
increase in PSD-95 protein expression levels. It is important to compare what changes occurred
in PSD-95 expression in individual pairs considering the ages of subjects varied. The p-values
for differences between control donors and ASD donors in terms of PSD-95 protein expression
for the two different brain areas analyzed in this study are shown in Table 6.
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Figure 6. Levels of PSD-95 protein expression in punch-dissected gray matter from frontal
cortex or BA10 (N=6; panel A) and anterior cingulate cortex or BA24 (N=5; panel B) using a
paired Student’s t-test. Target protein or PSD-95 in this figure was normalized to the reference
protein, GAPDH. No significant differences were found.

T-Test

P-Value
BA10

P-Value
BA24

Unpaired

0.4736

0.1221

Paired

0.5301

0.2547

Table 6. Statistical values of an unpaired and paired Student’s t-test for human postmortem
frontal (BA10) and cingulate (BA24) brain tissue of PSD-95 protein expression between ASD
and TD control tissue.

DISCUSSION
Previous studies have suggested that there is some sort of connectivity disfunction that
causes the social and behavioral deficits observed in autism. It is useful to acknowledge that
while MRI studies provide insight to what is happening structurally in the brain, these types of
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studies do not discuss what is occurring at the synaptic level. One emerging study urged future
studies to examine what is occurring pathophysiologically at the synapse, particularly the GABA
inhibitory signaling system, for these neurodevelopmental disorders often manifest from
“synapse to symptoms” (Coghlan et al, 2012). Other behaviorally diagnosed disorders such as
schizophrenia have been identified as important avenues for future research on synaptic protein
expression levels. Synaptophysin is another synaptic marker that is useful in providing insight to
any abnormalities that could occur at the synapse. While the specific function of synaptophysin
is unclear, some studies of another behavioral disorder, schizophrenia, have shown reduced
levels of synaptophysin in prefrontal cortex (Glantz & Lewis, 1997). This study and additional
papers on schizophrenia work to support the hypothesis that this disorder has alterations in
synaptic connectivity (Lewis & Liebermann, 2000). It has been established that there is a
disturbance in the circuitry and synaptic connectivity in patients diagnosed with schizophrenia.
Thus, proving the need for further research on synaptic activity and particular protein levels
through quantification as they may play a role in the pathophysiology of certain behavioral
diseases like ASD.
Although there was no statistical significance between control and ASD donor groups, there
are some takeaways to acknowledge from this study. Researchers are trying to distinguish
between schizophrenia and ASD as they are both behaviorally diagnosed. Up to this point, this
study was novel in its ASD research on spinophilin protein expression in human postmortem
brain tissue in frontal and anterior cingulate tissue. One study found decreased spinophilin
mRNA levels in four different brain areas of schizophrenic patients, compared to their normal
comparison subjects, suggesting a possible underlying dendritic pathology in schizophrenia (Law
et al, 2004). As autism is another behaviorally diagnosed mood disorder, it could be evident that
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excitatory or glutamatergic synapses display similar abnormalities. While our study did not find
any significant difference in spinophilin protein expression in frontal or cingulate brain tissue,
this is a significant finding in that it could be one distinguishable difference in the
pathophysiology of ASD and schizophrenia. More research is needed to solidify these findings,
but it could be a starting point.
The results for the IHC were disappointing. IHC is plagued by what is known as background
or nonspecific labeling of the secondary antibodies. It can interfere with the interpretation of the
specific protein being analyzed. Useable immunofluorescence requires that the fluorescence of
spinophilin be more distinguishable from the background; thus providing a more accurate
quantification in analysis. Tissue sections were imaged using the EVOS microscope to provide a
high-resolution picture. The images captured were taken in the gray matter, in consistent,
specific locations determined by landmarks. Gray and white matter human post-mortem BA10
brain tissue was examined and the positive and negative stain ultimately revealed no difference
in spinophilin expression above background or nonspecific staining. IHC was the initial
experiment of choice for distinguishable, identifiable morphological changes in neurons.
The spinophilin antibody could not be utilized for protein quantification using the brain
tissue; therefore, Western Blots, or immunoblotting was proposed. The alternative method of
using immunoblotting was executed because they serve as another technique to identify and tag
specific proteins in tissue samples. Similar to immunohistochemistry, an antibody is used in
immunoblotting to specifically detect its antigen in the sample. By creating a highly specified
interaction between a region of interest on the protein and a synthesized antibody, one can detect
the protein in a complex tissue sample such as brain tissue. This technique of immunoblotting
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provides an excellent visual comparison of how target protein expression can differ in response
to a condition or disease.
Limitations
A possible limitation of the immunoblotting experimentation is half the quantity was used of
the anterior cingulate (BA24) tissue as was used in the BA10 frontal cortical tissue for antibody
probing. Thus, less tissue will lead to lower protein that may not be sensitive enough for
antibody detection. We expected that the ratio of the target protein to the reference protein to be
the same in both brain areas. However, it was found that values in the cingulate or BA24 were
half the amounts in the frontal cortex. It could be that spinophilin and PSD-95 gene expression is
greater in the frontal cortex. Additionally, this study utilized GAPDH as a reference gene. The
reference protein should not change regardless of the condition, such as in in ASD or a typically
developing brain. However, it has been found that GAPDH may not be as reliable as previously
thought. Target proteins could be normalized to protein values obtained from a Poncheau S Stain
to ensure the integrity of GAPDH.
Another limitation of the immunoblotting could be attributed to reprobing the same blot for
several proteins. Multiple proteins were investigated for other research purposes on the same
nitrocellulose blot while spinophilin and PSD-95 were examined. Repetitive stripping and
reprobing with new primary antibodies could have caused the tissue samples to detatch as the
membrane becomes fragile. In this study, a pair was lost in cingulate tissue because GAPDH (the
last protein to be probed) expression was not quantifiable.

The western blot is a helpful tool, for when the results do not equal the expected data, it will
provide hints as to what actually went wrong. For example, if the band appears smaller than
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expected, that reveals that protein degradation has occurred and damaged the target protein. It is
possible that some of this protein degradation did occur, considering not all bands looked
identical when comparing the duplicate blots. With a small ‘n’ of 6 (BA10) and 5 (BA24), more
subjects must be added to this study in order to solidify these overall findings. The addition of
several more brain areas could prove advantageous to gaining more insight on any synaptic
abnormalities in ASD. For example, the amygdala which provides information as to the sensory,
or limbic system, could be a key area for future studies as it is involved in executive decision
making in the social brain pathway. Disturbances in gaze-following in humans has already been
related to impairments following damage to the normal role of the amygdala (Kennedy &
Adolphs, 2010). It is possible that these same impairments may be present in ASD
pathophysiology. It has also been theorized that difficulties in understanding and interpreting
facial expressions could be related to dysfunction of the amygdala in ASD (Kleinhans et al,
2010). Clearly, the amygdala should be considered in future research for its role in any social
deficits displayed in ASD. The cerebellum is another brain area that should be examined for
protein expression levels. With its role in language and cognition, there are implications to study
and distinguish any abnormalities in the structure of the cerebellum in ASD patients.
Future Studies
Alternative studies may also look to analyze other proteins involved in synaptic function and
regulation in the frontal cortex and anterior cingulate cortex. Insulin-like growth factor (IGF1) is
a molecule that can serve as a marker for inflammation, and it has been found to have increased
gene expression levels in the anterior cingulate cortex of ASD donors (Sciara et al, 2018). This
particular study proposed that in ASD, the signaling pathway of IGF1 may possibly be increased,
and thus play some sort of role in the complex etiology of this disorder (Sciara et al, 2018).
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While this study examined both gray and white matter of the ACC, evidence of an abnormality
may also be present in the frontal cortex of ASD post-mortem brain tissue.
Perhaps the most important variable to examine in ASD is age. Age is a factor that is
extremely revealing in ASD studies, as it is classified as a neurodevelopmental disorder. Thus,
there is a large demand for research on age differences in ASD. This study mainly analyzed older
donors (24-37 y/old) with only two pairs including younger individuals (16 and 22 y/old).
Perhaps the findings of protein expression levels could have been profoundly different if the
tissue donors were children, toddlers, or infants. A co-variant analysis in which age is examined
could be quite informative in future studies. Those will be performed when more subjects have
been added to this study. We completed a paired analysis of the data to account for age
difference, and to see if we overlooked any differences between the individual pairs. However,
the paired analysis did not reveal any evidence of overlooking any variables such as age.
Conclusion
This is the first study that examined Spinophilin protein expression in human postmortem
brain tissue in ASD. PSD-95 expression levels were also analyzed for comparison to typicallydeveloping and carefully matched controls since it has previously been explored in other brain
areas. Although no statistically significant differences were found in either brain region for both
spinophilin and PSD-95, these findings may be useful as guiding tool and precursor to other
research avenues. Very little is known regarding the precise etiology of this complex disorder
and these data serve to strengthen the present understanding. Absence of evidence does not have
the same meaning as evidence of absence. This study featured a small study sample and only
focused on two brain regions involved in the social behavior pathway. Future studies should aim
to include more subjects, if possible, and examine any potential synaptic deficits in other key
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brain areas such as the amygdala. Ultimately, any knowledge gained from these studies will aid
the field of autism research in precisely identifying the pathophysiology of this disorder that
could lead to developments in specific treatments.
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